Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2020 22:40 ET | Source: Viela Bio

Viela Bio Announces Pricing of Public Offering of Common Stock

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
May 26, 2020 07:23 ET | Source: Viela Bio

Viela Bio Announces Proposed Public Offering of Common Stock

GAITHERSBURG, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
May 13, 2020 16:15 ET | Source: Viela Bio

Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights

GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
May 13, 2020 16:10 ET | Source: Viela Bio

Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

-Safety profile comparable to placebo control- -Potent depletion of plasmacytoid dendritic cells in peripheral blood and skin biopsies- -Dose-dependent improvements in Cutaneous Lupus Erythematosus...
May 06, 2020 07:00 ET | Source: Viela Bio

Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020

GAITHERSBURG, Md., May 06, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
April 30, 2020 16:15 ET | Source: Viela Bio

Viela Bio Announces Election of Rachelle Jacques to its Board of Directors

GAITHERSBURG, Md., April 30, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
March 25, 2020 16:15 ET | Source: Viela Bio

Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
March 18, 2020 07:00 ET | Source: Viela Bio

Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
December 11, 2019 07:00 ET | Source: Viela Bio

Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome

GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
November 14, 2019 16:00 ET | Source: Viela Bio

Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

GAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...